-
Mérino, D, Khaw, SL, Glaser, SP, Anderson, DJ, Belmont, LD, Wong, C, Yue, P, Robati, M, Phipson, B, Fairlie, WD, et al.
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells..
Blood
119(24)
:
5807 -5816
2012
view publication
-
Roberts, AW, Seymour, JF, Brown, JR, Wierda, WG, Kipps, TJ, Khaw, SL, Carney, DA, He, SZ, Huang, DCS, Xiong, H, et al.
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease..
J Clin Oncol
30(5)
:
488 -496
2012
view publication
-
Khaw, SL, Huang, DCS, Roberts, AW.
Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies..
Pathology
43(6)
:
525 -535
2011
view publication
-
High, LM, Szymanska, B, Wilczynska-Kalak, U, Barber, N, O'Brien, R, Khaw, SL, Vikstrom, IB, Roberts, AW, Lock, RB.
The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs..
Mol Pharmacol
77(3)
:
483 -494
2010
view publication
-
Khaw, SL, Huang, DC, He, S, Seymour, JF, Carney, D, Mason, KD, Chyla, B, Litvinovich, E, McKeegan, E, Krivoshik, A, et al.
Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)..
Blood
114(22)
:
2374
2009
view publication